Meet the Team
Ph.D. Founder & CEO
Omer Porat, PH.D., is a neuropsychologist passionate about improving the lives of individuals suffering from various health conditions, particularly those related to brain aging and cognitive decline. His doctorate in cognition in Parkinson's disease provided a strong foundation for his work in this field. In 2018, Omer filed a patent for the targeted transport of brain-protective nutrients, which he believed could preserve and improve brain functions in old age. This idea evolved into Nutaria, a startup company that has secured funding from prestigious sources such as the Innovation Authority and international partners, including IFF-DuPont. As the CEO and Founder of Nutaria, Omer has brought his dream to life and has created a company dedicated to improving people's lives through innovative brain health solutions. His expertise in neuropsychology and commitment to improving brain health make him a respected leader.
PhD, MPharm. VP R&D
Clinical Pharmacology, AFHEA
Dr. Hassan Elsana is an accomplished professional scientist specializing in pharmaceutical and biopharmaceutical research. With expertise in drug delivery, stability, immunology, and pharmacology. Dr. Elsana completed his Ph.D. in nanoparticle-based gene and drug delivery systems at the University of Sunderland, UK. His research focused on developing innovative solutions for effective therapeutic delivery. Dr. Elsana has published in reputable journals, including Current Drug Delivery Journal and British Journal of Pharmacy, and has presented his findings at conferences worldwide. With a strong commitment to advancing pharmaceutical research, Dr. Hassan Elsana continues to drive impactful innovations in drug delivery and biopharmaceutical sciences.
Head of the Board of Directors (MBA, LLB)
seasoned entrepreneur with extensive experience in leading companies from the feasibility to commercialization stages. He currently serves as the Chairman of the Board of Directors of Nutaria, a leading food tech company. In addition, he is the former CEO of Millennium Food Tech VC, where he led investments in advanced-stage food ventures. Prior to his role at Millennium Food Tech VC, Chanan served as the CEO of Fresh-Start, a prominent startup accelerator with partners including Tempo, Tnuva, ourcrowd, and Finistere Ventures. Throughout his career, Chanan has demonstrated a deep understanding of the food industry and has helped numerous companies succeed through his strategic guidance and leadership.
David Vita, the GM and Founder of MAKWA Strategy and Investments, is an audacious and boundary-pushing business development expert at Nutaria, a foodtech startup. With a remarkable track record in establishing production facilities and sales channels abroad, David excels in navigating diverse business environments. Their adeptness in managing all aspects of the company's growth and development, from initial financing to eventual listing, has been instrumental in Nutaria's success. Beyond their business accomplishments, David's coaching skills in multiple languages, including English, Italian, French, and Hebrew, have fostered the professional growth of individuals. With an unwavering entrepreneurial spirit, linguistic versatility, and hands-on management style, David Vita continues to make a profound impact in Nutaria's growth.
Dr. Moshe (Motzi) Neuman
Bio Medical Research Design.
Dr. Moshe Neuman is a seasoned professional with over 25 years of experience in the pharmaceutical, biotechnology, and medical device research & development fields. He is the President and CEO of Bio-Medical Research Design Ltd. (B.R.D), and the Regulatory Advisor for Nutaria. He has vast regulatory knowledge spanning FDA (US), EMA (EU), and ICH regulations. Dr. Neuman specializes in Regulatory Affairs Consulting, Drug Development, and Clinical Trial Design and Management. He also provides full Contract Research Organization (CRO) services for Phase I to Phase IV studies. He is a Certified GCP Auditor for Clinical Trials and offers GCP Training. Dr. Neuman's expertise is helping Nutaria to navigate the regulatory landscape and bring its targeted delivery products to market.
Head of the Scientific Advisory Board.
Professor Emeritus at Tel-Aviv University Medical School (Neurology)
Professor Korczyn, an esteemed authority in neurodegenerative diseases, is Nutaria's Head of Scientific Advisory Board. He completed his MD and an MSc degree in Pharmacology, both cum laude, from the Hebrew University–Hadassah Medical School, Jerusalem, in 1966. His extensive training in Neurology took place at Beilinson Hospital and the National Hospital for Nervous Diseases, Queen Square, London. He led as the Chairman of the Department of Neurology at the Tel-Aviv Medical Center from 1981 to 2002, additionally holding the distinguished Sieratzki Chair of Neurology at Tel-Aviv University between 1995 and 2010. His contributions to the field of neurology include over 700 peer-reviewed articles, many book chapters, and several edited books and special issues in journals. He's also recognized as the Regional Editor for the Journal of Alzheimer's Disease and serves on the editorial boards of 20 international journals. Professor Korczyn's expertise extends to organizing neurological conferences primarily focused on dementia, Parkinson’s disease, and other degenerative brain disorders. He has been a key figure in orchestrating the International Congress on Controversies in Neurology (CONy) and the Mental Dysfunction in Parkinson's Disease congresses since 1993. In addition to his role at Nutaria, Professor Korczyn is the Chairman of the Scientific Medical Board of the Israeli Alzheimer's Disease Association (EMDA). He's also a member of the Scientific Advisory Board of Alzheimer Disease International (ADI), and previously chaired the WFN Research Committee for Clinical Neuropharmacology. His service extends to advisory boards in several drug discovery programs, further showcasing his remarkable influence in the field of neurology.
Pinni Raveh is a seasoned executive with a passion for biomedical innovation. He has played a key role in the success of several digital health startups, including Nutaria. At Nutaria, Pinni has been instrumental in securing $20 million in funding, developing targeted delivery food supplements, and growing annual revenues from $0 to $15 million. Pinni is a highly motivated and results-oriented leader who is dedicated to pushing the boundaries of biomedical innovation and shaping the future of healthcare. Pinni's contributions are helping Nutaria to become a leader in the foodtech industry. He is a valuable asset to the company and is helping to make a positive impact on the health of people around the world.
Prof. Daphne Atlas
Professor Daphne Atlas is a highly respected figure in the scientific community, with significant contributions to both higher education and biomedical research. She began her academic journey at The Hebrew University, focusing on Chemistry Biochemistry, before furthering her studies in Biophysics at the Weizmann Institute. Professor Atlas has made substantial strides in the field of medical science, developing innovative therapeutics for Parkinson's disease and other health conditions. She pioneered the development of Dopamide (ND-0901), a derivative of L-DOPA, which is currently in clinical trials by NeuroDerm/Mitsubishi. Moreover, she spearheaded the creation of NAC-amide (NACA), also known as AD4, now in Phase II clinical trials by Nacuity, Texas. Today, she serves on the Scientific Board of Nutaria LTD., applying her extensive knowledge and unwavering commitment to advancing biochemistry's practical applications. Her work continues to drive scientific exploration and improve human health.